Elizabeth (Lisa) Petri Henske is the Director of the Center for LAM Research and Clinical Care at Brigham and Women’s Hospital. She is a graduate of Yale University (summa cum laude) and Harvard Medical School. She is Professor of Medicine at Harvard Medical School, an Associate Member of the Broad Institute of MIT and Harvard, and a practicing medical oncologist at the Dana-Farber Cancer Institute. LAM (lymphangioleiomyomatosis) is a destructive lung disease that affects almost exclusively women, with an increased rate of progression during pregnancy. Dr. Henske’s laboratory made the pivotal discovery that (LAM) is caused by mutations in the tuberous sclerosis complex 2 (TSC2) gene, leading to clinical trials demonstrating efficacy of mTORC1 inhibitors. She also was the first to discover that the TSC1 and TSC2 proteins physically interact. Her research laboratory is focused on the cellular, metabolic, and immunologic mechanisms underlying the pathogenesis of tuberous sclerosis complex (TSC) and LAM, supported by multiple grants from the National Institutes of Health. She is a member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Henske has received awards for her research from the Tuberous Sclerosis Alliance, The LAM Foundation, the American Thoracic Society, and the Society for Women’s Health Research (the Medtronic Prize).